Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Regulus Resources (CVE:REG) stock is up 137% in the last year, providing strong gains for shareholders. But the ...

I pick out North America’s celestial highlights for the week ahead (which also apply to mid-northern latitudes in the northern hemisphere).

February's full Snow Moon will have a royal companion as it rises alongside Regulus, a star nicknamed "Heart of the Lion", ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 23.00%, which has investors questioning if this is right time to ...

Stargazers are in for a treat as February's Full Snow Moon is set to brighten the night sky on Wednesday, 12th 2025.

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program.

Regulus (RGLS) Therapeutics announced positive clinical and regulatory updates from its ADPKD program. The update includes positive topline results from an interim analysis of the fourth cohort of ...